The efficiency of rosuvastatin and pulmonary rehabilitation usage in patients with asthma and COPD with comorbid diabetes mellitus type 2.

Abstract

Numerous studies show the effectiveness of long-term pulmonary rehabilitation programs for COPD. However, there are few studies demonstrating the effectiveness of short-term programs, especially in patients with concurrent symptoms of asthma and COPD. The pleiotropic properties of rosuvastatin, particularly the reduction of systemic inflammation and the suppression of processes such as NETosis, suggest the potential effectiveness of its use in patients with a combination of asthma, COPD and diabetes mellitus type 2. The aim of the study. To investigate the impact of a pulmonary rehabilitation program combined with 10 mg of rosuvastatin daily, in addition to the basic treatment prescribed, on the quality of life and exercise tolerance of patients with asthma, COPD and diabetes mellitus type 2.